RBC raises target for Vertex Pharma stock from USD 570 to USD 576

Published on 10/09/2026 at 16:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Inaxaplin cut UACR 42.70 percent from baseline on September 22, 2026. Vertex Pharma stock costs EUR 458.98 on October 9, 2026 versus EUR 448.90.

Key points in brief

RBC raised its Vertex Pharmaceuticals price target from USD 570.00 to USD 576.00 on October 8, 2026.
Vertex Pharma stock was trading at EUR 458.98 at Lang & Schwarz on October 9, 2026, plus 2.25 percent versus the prior close.
Second-quarter 2026 revenue reached USD 3.33 billion, up 12.50 percent year over year.
Vertex will report third-quarter 2026 results on November 2, 2026, after the market close.

Wissenschaftler pipettiert Proben in modernem Biotech-Labor mit Automatisierungsgeräten — Vertex Pharma US92532F1003 zeigt einen Forscher im modernen Labor mit Pipette an sterilem Edelstahltisch, Illustration mit AI erstellt.

Vertex Pharma (ISIN US92532F1003) was trading at EUR 458.98 at Lang & Schwarz on October 9, 2026 at 4:14 p.m. CEST, up 2.25 percent versus the prior close of EUR 448.90. According to Aktiencheck on October 8, 2026, RBC Capital Markets raised its target for Vertex Pharmaceuticals from USD 570.00 to USD 576.00 while keeping an Outperform rating.

What does the target change add?

The RBC target increased by USD 6.00, equal to 1.05 percent versus the former USD 570.00 target. The research note gives the stock a concrete near-term valuation reference, while the euro quotation remains the relevant price for investors trading through Lang & Schwarz.

Vertex's latest operating figures provide a second reference point. In the second quarter of 2026, revenue reached USD 3.33 billion, up 12.50 percent year over year, while GAAP net income was USD 1.10 billion, up 6.50 percent, according to Financial Report Insights.

Three dated pipeline signals

On August 3, 2026, Vertex reported second-quarter revenue of USD 3.33 billion, up 12.50 percent year over year, according to Financial Report Insights. On September 22, 2026, its inaxaplin AMPLIFIED study showed a 42.70 percent reduction in urine albumin to creatinine ratio from baseline in one cohort, as FinanzNachrichten reported from the company release. On October 8, 2026, RBC Capital Markets lifted its target from USD 570.00 to USD 576.00, according to Aktiencheck.

Next date is November 2

Vertex will report third-quarter 2026 financial results on November 2, 2026, after the market closes, and will host its earnings call at 4:30 p.m. ET, according to the company's Vertex Pharmaceuticals release dated October 7, 2026.

Vertex Pharma stock in afternoon trading

At Lang & Schwarz, Vertex Pharma stock stood at EUR 458.98 on October 9, 2026 at 4:14 p.m. CEST, up 2.25 percent against the EUR 448.90 prior close. The primary Nasdaq listing was last quoted at USD 512.39 on October 9, 2026 at 10:25 a.m. EDT, while market capitalization stood at USD 130.0 billion.

The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.